Detection of allele specific differences in \textit{IFNL3} (\textit{IL28B}) mRNA expression

Susanne Knapp\textsuperscript{*}, Naeem Meghjee, Sorcha Cassidy, Khaleel Jamil and Mark Thursz

Abstract

\textbf{Background:} Variants of the interferon-lambda3 (\textit{IFNL3}) gene have been associated with both spontaneous and treatment induced clearance of HCV infection. Attempts to link polymorphisms of the \textit{IFNL3} gene with variation in the level of \textit{IFNL3} expression have been inconclusive. This is partially due to the difficulty to design assays distinguishing \textit{IFNL3} from \textit{IFNL2}.

\textbf{Methods:} In this study an allele specific real-time PCR (RT-PCR) assay was developed which allows the relative quantification of the two \textit{IFNL3} transcripts in cells heterozygous for SNP \textit{rs4803217} in the \textit{3'-UTR} of the \textit{IFNL3} gene. This SNP is in strong linkage disequilibrium (LD) with the predictive marker \textit{rs12979860}.

\textbf{Results:} Raji cells showed two-fold increased levels of \textit{IFNL3.rs4803217} C-allele expression. In peripheral blood mononuclear cells (PBMCs) of eight uninfected donors, two donors showed increased \textit{IFNL3.rs4803217} C-allele expression.

\textbf{Conclusion:} This indicates that allele specific differences in \textit{IFNL3} expression vary between individuals and might contribute to the variety of outcomes in HCV infected patients.

\textbf{Keywords:} Variation of allele specific expression, Quantitative RT-PCR, \textit{IFNL3} gene, Hepatitis C Virus (HCV) infection, in vitro assay

\textbf{Background}

Recently genetic polymorphisms in the interferon-lambda3 gene (\textit{IFNL3}), also known as interleukin 28B (\textit{IL-28B}) have been shown to be highly associated with the outcome and treatment response of Hepatitis C infection in ethnically diverse cohorts [1-6]. Several single nucleotide polymorphisms (SNPs) are in linkage disequilibrium (LD), which makes the identification of the functional polymorphism challenging. Attempts have been made to link the effects of the polymorphism to a difference in the level of expression of \textit{IFNL3} transcript \textit{in vitro} and \textit{in vivo} [4,7] or differences in potency of the corresponding gene products [8], but no consistent difference could be detected.

The challenge with designing genotyping assays for \textit{IFNL3} is the close homology with \textit{IFNL2} (\textit{IL28A}), with which it shares 96% homology on the DNA level [4,9]. Several \textit{IFNL3} specific TaqMan assays have been designed which discriminate \textit{IFNL3} from \textit{IFNL2} [8,10], but are not able to discriminate between the two alleles within the gene. In order to study the allele specific expression of \textit{IFNL3}, we developed a SYBRGreen based RT-PCR assay which is able to quantify the two allele specific transcripts of \textit{IFNL3} (whilst excluding a signal from \textit{IFNL2}) based around the two expressed alleles of the \textit{rs4803217} SNP in the \textit{3'-UTR} region of \textit{IFNL3}. In the Asian and Caucasian population SNP \textit{rs4803217} is in close LD with \textit{rs12979860} (\textit{r}^2 = 0.98 [11,12]), which predicts outcome of HCV infection and treatment response. The relative amount of allele specific transcript was measured after interferon stimulation of Huh7, Raji and Jurkat cells, and in peripheral blood mononuclear cells (PBMCs) of eight uninfected healthy donors, which were heterozygous for \textit{IFNL3.rs4803217}. The assay is a modification of allele specific quantitative RT-PCR, which has been developed by Germer \textit{et al.} [13] to accurately measure varying allele frequencies between 5% and 95% for SNPs in pooled DNA samples. We report that the presented \textit{IFNL3} specific assay is able to accurately measure variation of allele specific expression between individuals.
Methods

Cell lines

The cell lines used in our experiments were Huh7, Raji and Jurkat cell lines. The Huh7 cell line is derived from hepatocellular carcinoma [14]. The Raji cell line is a suspension cell line derived from B-lymphocytes [15]. The Jurkat cell line is derived from T-cells [16].

Huh7, Jurkat, and Raji cells were cultivated under standard conditions in DMEM medium containing 5% Pen/Strep and 10% heat inactivated Foetal Calf Serum (FCS) and incubated at 37°C under 5% CO2/air. Confluent Huh7 and stationary phase Raji and Jurkat cells were diluted to 2 x 10^5 cells/ml into 1 ml of medium in 12-well plates. On the following day, the number of cells reached 4 x 10^5 cells/ml, cells were stimulated by adding interferon alpha (IFNα) (30–2000 Units/ml; Roferon, Roche) [17], interferon beta (IFNβ) (50–1000 Units/ml; human interferon β1a, Sigma) [18], interferon gamma (IFNγ) (50–500 ng/ul; R&D systems) [19], interferon lambda 3 (IFNλ3) (IL-28B 500 ng/ml; R&D systems) [20], toll like receptor 7 (TLR7) agonist RWJ21757 (10 μmol; R&D systems) [21] or tumour necrosis factor alpha (TNFα) (40 ng/μl; R&D systems) [22].

Huh7, Raji and Jurkat cells were tested for the expression of interleukin 10 receptor beta (IL10RB), interferon alpha receptor (IFNαR), IFNL2/3 IL28, 2'-5'-oligoadenylate synthetase (OASI) and myxovirus (influenza virus) resistance 1 (Mx1) (with GAPDH as a housekeeping gene) using primers published by Diegelmann et al. [23].

Peripheral Blood Mononuclear cells (PBMCs)

Peripheral blood mononuclear cells (PBMCs) from eight consented uninfected donors heterozygous for the IFNL3. rs4803217 polymorphism were isolated using Hypaque-Ficoll (Amersham Biosciences) density centrifugation. 1–5 x 10^6 cells in 1 ml of medium were stimulated with 800 Units/mls IFNα for 6 hours.

Genotyping of cell lines and healthy donors

SYBRGreen based RT-PCR was used to characterize the genomic DNA of cell lines and uninfected donors for the IFNL3 polymorphisms rs12979860, rs8103142 and rs4803217. The schematic location of these SNPs and their pairwise linkage disequilibrium is shown in Figure 1A. Primers were designed by the author to be specific for IFNL3 and ordered from Invitrogen. Primer sequences are listed in Table 1. The position of the three primers for the rs4803217 RT-PCR assay within the sequence of IFNL2/3 is illustrated in Figure 1B.

Each DNA sample was interrogated twice, once with the primers specific for allele 1 (A) in combination with the common primer, then with the primer specific for

![Figure 1 Schematic location of the rs4803217 SNP in relationship to other SNPs in and near the IFNL2/3 gene. All four variants are in high linkage disequilibrium in Caucasians (r^2 ≥ 0.92) [12]. The linkage disequilibrium between the four markers is represented in the table below the diagram and displayed as r^2 (10;32), with a lower linkage disequilibrium reported between rs12979860 and rs8099917 [11].](image)
allele 2 (C) in combination with the same common primer. The genotyping method using the primer combination for IFNL3.rs12979860 has been described earlier [24].

Reactions were performed in 96 well plates with 10 ng/µl genomic DNA and 0.5 µM of each primer (one allele specific and one common primer per reaction) in the presence of a SYBRGreen containing reagent mix (QuantiTect, Qiagen) using a StepOnePlus instrument (Invitrogen). The cycling conditions were initial denaturation of 10 min 95°C, 40 cycles of 15 seconds 95°C and 60 seconds 60°C, followed by a melt curve.

Genomic DNA for the validation of the method was used as 10 ng/µl after quantification with a NanoDrop spectrophotometer (Thermo Fisher).

cDNA synthesis
RNA was extracted from cells following the RNasey protocol (Qiagen) and from frozen PBMCs of uninfected donors using Trizol reagent (Invitrogen) in a standard protocol (Qiagen) and from frozen PBMCs of uninfected donors using Trizol reagent (Invitrogen). cDNA was synthesized using the Retroscript kit (Ambion) according to manufacturer’s instructions, but using oligo dTs and random decamers (2.5 µM each) in combination to optimize the efficiency of the cDNA synthesis. 1µg of RNA was transcribed into cDNA.

Relative quantification of gene expression by real time PCR
The same assay, including conditions and primers, which was used for genotyping was also used for relative quantification of allele specific gene expression. But in contrast to the genotyping assay, samples were run in triplicates for each allele specific reaction. 1 µl of a 20 µl of cDNA (cDNA from 50 ng of RNA) volume was put in each reaction. In order to use the assay for quantification of allele specific expression, the bias induced by the difference in amplification efficiency between the two allele specific reactions was corrected for by the use of a heterozygous genomic control in each experiment.

In order to validate the genotyping assay for its use in detecting potential 1.5 to 2 fold differences between the expression of the two alleles of IFNL3.rs4803217, different ratios of the two alleles from two DNAs homozygous for the respective alleles were combined and their respective dCt (difference between Ct value of allele 1 and 2) measured using the IFNL3.rs4803217 genotyping assay. Assuming both allele specific primers have the same amplification efficiency of the assay, the reaction specific for allele1 should get amplified after the same number of amplification cycles than allele 2, and dCt should be zero for a heterozygous sample carrying the same amount of allele 1 and 2. The same results (with exception of DNA measurement and pipetting errors) should be approximated if allele 1 and allele 2 are combined in a 1:1 ratio from the two homozygous DNA samples. If the alleles are present in a ratio 1:2, with allele 2 having twice the frequency of allele 1), then allele 2 should get amplified one cycle earlier (as each cycle leads to duplication of the number of amplified copies) and the dCt should be 1. Therefore the relationship between ratio and dCt is represented by equation [1]: Ratio = 1:2<sup>dCt</sup>. Allele 1 (A) and 2 (C) were combined in ratios 4:1, 3:1, 2.5:1, 2.1, 1.5:1, 1:1.5, 1:2, 1.2:5, 1:3, 1:4.

The results were corrected with the dCT of the heterozygote genomic DNA control (HH23), which compensates for the difference in amplification efficiency of the two alleles. The relationship between known ratios of the two alleles and measured dCt values is shown in Figure 2.

The inability of the assay to discriminate against genomic DNA present in the sample is off-set by the advantage of internal validation using three sequenced genotyping controls. As the genomic DNAs of the cells tested for variation of allele specific PCR are heterozygous for the SNP which the assay is detecting, they cannot contribute to variation in allele specific expression. Therefore any observed variation (after correction for the bias introduced through unequal amplification efficiency of the two allele specific reactions which is calculated by including a genomic heterozygous control in each assay) can be attributed to a variation in allele specific expression. RNA (without reverse transcription) controls were also included in each assay in order to detect amplification resulting from genomic DNA in the cDNA.

### Statistical analysis
Data were analysed using Graph Pad Prism. The Mann–Whitney U test was applied to compare the means of the difference in allele expression between heterozygote

---

**Table 1 Primer sequences for IFNL3 genotyping and expression studies**

| SNP           | Location       | Allele specific primer (5' > 3') | Common primer (5' > 3') |
|---------------|----------------|--------------------------------|-------------------------|
| rs12979860    | 3 kb upstream  | gcattcaacctggcttcA              | gcttatgcatacggctaggc    |
|               |                | gcattcaacctggcttcG              |                         |
| rs8103142     | exon 2 (K70R)  | cttctgctgaaggacctgcaA           | tgaagggcgggtgagaag      |
|               |                | cttctgctgaaggacctgcaG           |                         |
| rs4803217     | 3'UTR          | cgactggggtgacataaatagA           | cctgtgtgtctgacccctcc   |
|               |                | cgactggggtgacataaatagC           |                         |
genomic controls and cDNA in stimulated cells from four experiments in Raji cells, using three independently synthesized batches of cDNA from two independent stimulation events. Data obtained from the eight uninfected donors were analyzed in the same way. Two tailed p-values are calculated. Data are expressed as mean +/- SEM.

Results

Genotyping of cell lines and healthy donors

The rs4803217 RT-PCR assay is specific for IFNL3 (Figure 1B), as it distinguishes three genotypes (Figure 3). It excludes the amplification of IFNL2, which has the A allele "fixed" in the position of the rs4803217 SNP (3’ end of the specific primer). Cross reactivity with IFNL2 would not allow the detection of CC homozygocity if this primer also recognized the A allele of IFNL2. The differences between the crossing points (dCt values) for the two alleles of IFNL3.rs4803217 is robustly greater than dCT = 6 for homozygotes AA or CC in the absence of the other allele, whereas in heterozygotes the average dCt between the two allele specific reactions varies between 0.06 and 1 (assay variability) which is the result of the difference in amplification efficiency for the two alleles. To further confirm the IFNL3 and allele specificity of the rs4803217 assay, we sequenced amplicons which suggested AA and CC homozygocity respectively from samples which had been used as controls in each assay. We confirmed that the products were IFNL3 and allele specific (Additional file 1: Figure S1: Sequence of amplification products).

Huh7, Jurkat and Raji cells are heterozygous for the IFNL3.rs12979860, IFNL3.rs8103142, and IFNL3.rs4803217 polymorphisms (Figure 1A), thus making it an ideal system for the relative comparison of the expression levels of the two alleles. RNA controls revealed that only negligible amounts of genomic DNA were present in the cDNA samples used. Eight uninfected donors heterozygous for rs4803217 were also heterozygous for rs12979860 and rs8103142, which confirms the strong linkage disequilibrium between the three markers.

Relative quantification of gene expression by real time PCR

Huh7, Raji and Jurkat cells showed constitutive expression of IL10RB, IFNaR and inducible expression of IFNL2/3, OAS1 and Mx1 (with GAPDH as a reference) after stimulation with 800 iU/ml IFNa, indicating that the receptors for the recognition of the IFN stimulation are intact and IFNL2/3 is induced. Additional file 2: Figure S2 (induction of OAS etc after IFNa stimulation) shows the induction of OAS and IFNL2/3 in Huh7 cells after 3, 6, 8, 12 and 24 hours of stimulation with 800 iU IFNa.
Initial dose response experiments demonstrated that induction of IFNL3 expression was optimal using 800 IU/mLs IFNα and 6 hour incubation (see also Additional file 2: Figure S2 (gene induction)). Therefore IFNL3 expression for this manuscript was measured following this protocol. IFNβ showed the best induction after 6 hours of 500 IU/mLs IFNβ, and IFNλ at 500 ng/mL. Both were less efficient in the induction of IFNL3 expression and did not lead to reproducible comparisons of allele specific IFNL3 expression. Toll like receptor 7 (TLR7) agonist RWJ21757 and tumor necrosis factor alpha (TNFα) were unable to induce detectable levels of IFNL3 expression in Huh7 cells (data not shown) and were not tested in Raji or Jurkat cells.

As the validation experiment shows, the IFNL3.rs4803217 allele specific PCR assay is able to measure the relationship between dCt and 1.5-2 fold changes in the ratio of the two specific alleles (Figure 2). We therefore concluded that the assay for IFNL3.rs4803217 is suitable to measure a difference in the expression of the two alleles in cells heterozygous for the IFNL3.rs4803217 SNP.

Using the IFNL3.rs4803217 genotyping based quantitative RT-PCR assay, we detected a two-fold increased expression of IFNL3.rs4803217 C specific transcript in Raji cells in four independent experiments (fold-change 2.09 (95% CI = 0.94-1.07) versus 1.01 (95% CI = 1.50-2.70), p = 0.029). The combined result of the four experiments is represented in Figure 4. In order to validate the results in primary cells we looked at allele specific IFNL3 expression in eight healthy donors heterozygous for the IFNL3.rs4803217 polymorphism. The relative expression levels of the two alleles showed variation between individuals, with ratios of C to A allele ranging between 1.4 and 0.7. Two of the eight donors showed an increased IFNL3.rs4803217 C allele expression. The results were reproducible for each individual. The differences in the ratios did not reach statistical significance (Figure 5). Due to the relatively low expression of the IFNL3 gene in the B cells of uninfected subjects [23], we were unable to measure allele specific IFNL3.rs4803217 expression in their B cells (data not shown).

Discussion
In order to develop an assay that is able to measure the expressed products of IFNL3 in an allele specific manner, the 3'UTR SNP rs4803217 was chosen, as it is in strong linkage disequilibrium with rs12979860, a predictive marker for the clinical outcome of HCV infection and treatment response. The assay clearly excludes the amplification of IFNL2 specific sequence as it shows the distinction of three genotypes including AA homozygocity, which would not be possible if the C allele of IFNL2 was present. In addition our assay is also able to discriminate between the two variants of the IFNL3.

![Figure 4](image4.png)

**Figure 4** Relative level of IFNL3.rs4803217 C-allele specific transcript detected in Raji cells heterozygous for IFNL3.rs4803217 after stimulation with 800 IU IFNα, compared to a genomic heterozygote control. The ratio of CA allele is expressed as 2^dCt after correction with the differences observed in the genomic heterozygote control. The results of 4 independent experiments are shown. The p-value 0.029 was calculated using the Mann–Whitney U test.

![Figure 5](image5.png)

**Figure 5** Relative levels of IFNL3.rs4803217 C-allele specific transcript detected in frozen PBMCs from eight uninfected donors heterozygous for IFNL3.rs4803217 after stimulation with 800 IU IFNα, compared to a genomic heterozygote control. The ratio of CA allele is expressed as 2^dCt value after correction with the differences observed in the genomic heterozygous control.
rs4803217 polymorphism. Using this assay we observe increased expression of the IFNL3.rs4803217 C allele in Raji cells at 2 fold level. No difference in the relative level of allele specific expression was observed for Huh7 and Jurkat cells. Raji cells are derived from a B-cell line, where high levels of IFN-λR have been detected, suggesting that B-cells are actively involved in IFNL3 signalling [25]. Raji cells are reported to produce higher levels of IFNL3 compared to Huh7 or Jurkat cell lines [10], which supports the finding that allele specific differences of expression can be context and tissue specific [26]. Unfortunately expression of IFNL3 in the B-cell population of the healthy donors resulted in undetectable levels of IFNL3 due to the low expression of IFNL3 and smaller number of cells available (data not shown).

In order to validate our assay in primary cells, we selected eight uninfected donors heterozygous for rs4803217 and rs12979860. The C allele was up-regulated in two of the eight donors. We detected marked variation in the relative ratio between the C and A allele, ranging from 1.4 to 0.7. Although this variation is not as high as the 2 fold increase as the expression of the C allele in Raji cells, and not as clear cut as a 1.5 ratio from the standard curve in Figure 2, the ratio was clearly reproducible for each donor.

The C allele of IFNL3.rs4803217 is in LD with the C allele of IFNL3.rs12979860, which is associated with a high frequency of clearance and treatment response. Our results indicate that in certain cells or individuals the rs12979860 CC and also CT genotype are possibly producing more IFNL3 transcript than the TT genotype, an observation which had been reported earlier using whole blood samples [4], but was not confirmed in liver tissue [8]. In contrast to Suppiah's approach [4] where allele specific variation is measured by comparing IFNL2/3 expression in individuals homozygous for the two alleles of rs12979860, our assay is specific for IFNL3 and is carried out in heterozygotes, so that a comparison of expression between the two alleles within the same cell is less likely to be subject to confounding variables. Our results obtained in eight uninfected healthy donors heterozygous for the IFNL3 SNP rs4803217 (and consequently rs12979860) suggests that variation exists between individuals with regards to allele specific expression. As we only study the differences observed in the allele specific expression of heterozygotes, we cannot exclude that homozygosity of each of the alleles could result in a greater effect of the genotype variation.

Variation in allelic gene expression affects 20-50% of human genes and may account for variation in the transmission of diseases and disease outcomes [27-29].

It has been reported that differences in allele specific expression are inherited, but that only 3-30% of individuals exhibit the allele specific expression [27]. It was shown that allelic variation in the adenomatous polyposis coli (APC) gene expression plays a critical role in colon cancer [30]. Variation in allelic expression was also measured for the rs2834167 SNP in IL10RB in Epstein Bar virus (EBV) transformed B-cell line heterozygous for this SNP and might be the underlying functional cause for the association of this SNP with the outcome of HBV infection [31].

In the literature conflicting results are reported with regards to IFNL3 expression in PBMCs versus liver, and differences seem to exist between healthy and chronic donors. In our technical manuscript we use PBMCs of healthy donors to develop the assay as a tool which is able to measure IFNL3 and allele specific expression of IFNL3 transcripts in patient cohorts. A few publications have shown a potential role of blood and immune cells in the recruitment process to the liver during inflammation. Although the expression status of cells might differ between healthy donors and during the process of inflammation, PBMCs are a valid starting point for measuring allele specific expression of IFNL3 [32].

As we did not find consistent up-regulation of the C allele in eight donors heterozygous for the C allele of IFNL3.rs4803217 and rs12979860, we investigated the possibility that the observed variation in expression of the rs4803217 C transcript is influenced by other SNPs in the IFNL3 region. It has been reported that a new variant upstream of the IFNL3 gene, which is in high linkage disequilibrium with rs12979860, and leads to a frameshift mutation creating a new interferon gene IFNL4, might explain the association with the clinical outcomes of HCV infection [33]. It has been noted that the expression of the IFNL3 gene is dependent on the genotype of the novel ss469415590 SNP [34]. Genotyping all donors in our study for ss469415590 revealed that they were all heterozygous for ss469415590, thus excluding the possibility of an influence of this variant.

In the three cell lines and eight donors heterozygous for IFNL3.rs4803217 we find 100% linkage with the IFNL3.rs12979860 marker. High LD between both markers is characteristic for Asian and Caucasian populations [12] (HapMap database r2 = 0.9 and 0.7-0.8 respectively), but reported to be at r2 = 0.4 for Sub-Saharan samples. More recently it was shown that the IFNL3. rs4803217 variation seems to affect the stability of the transcript, which could be another way by which the IFNL3 polymorphism exerts its function [35]. Our finding of varying C:A allele expression in certain cells and individuals could be a result of differential stability of the transcript in different individuals. Further studies need to be undertaken to explore the function of the rs4803217 polymorphism in the outcome of HCV infection and treatment response, using an IFNL3 and allele specific assay for rs4803217.
Conclusion
In conclusion, we show that the allele specific assay for IFNL3 which we developed is a useful tool to determine the IFNL3.rs4803217 genotype and at the same time accurately and directly compare the expression of two alleles of the IFNL3 gene within heterozygous cells. As the rs4803217 SNP has been reported to have an effect on the stability of the transcript [35] the developed assay could be used for the measurement of allele specific IFNL3 expression in patient groups with different HCV outcomes and treatment response, to determine the clinical relevance of the observed variation.

Additional files

Additional file 1: Figure S1. Sequences of amplification products of IFNL3 allele specific rs4803217 assay. A: The products are IFNL3 specific at position 11 from the 5’end of the forward primer (starting from GCT; A is not part of the primer sequence), where IFNL3 is characterized by a T(allele), whereas IFNL2 has a C(G) allele. The T(A) specific primer amplified the T(TAA) homozygote, whereas the C(G) specific primers amplified the GG (CC) homozygote. 5’ and 3’ describe the direction of the primer extension during the amplification.

Additional file 2: Figure S2. Induction of OAS and IFNL2/3 by 800IU IFNa after 3, 6, 8, 12 and 24 hours.

Competing interests
The authors declare that they have no competing interests.

Authors’ contribution
The project (assay design, validation, cell culture and quantitative RT-PCR, writing of manuscript and preparation of figures) was carried out by SK. NW helped with the setting up of dose response curves under the supervision of SK. SC and KJ have collected and prepared the PBMCs of the uninfected donors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors acknowledge funding by the EU framework seven (FP7) grant 260844 awarded to MT. SK was funded by the EU framework seven (FP7) grant 260844. NW was a BSc student at the time of the conception of the project. SC and KJ were supported by the Wellcome Trust. All authors acknowledge support from the Imperial College Biomedical Research Centre. SC and KJ have collected and prepared the PBMCs of the uninfected donors of the PBMCs of the uninfected donors. The funders had no role in study design, data analysis and interpretation, decision to publish, or preparation of the manuscript. All authors read and approved the final manuscript.

Received: 23 August 2013 Accepted: 5 September 2014
Published online: 05 October 2014

References
1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Afdhal N, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461(7262):399–401.
2. Thomas DL, Thi0 CL, Martin MP, QY Y, Ge D, O’Huglin C, Kidd J, Kidd K, Khakoo S, Alexander G, Goedert JJ, Kirt KG, Donfield SM, Rosen HR, Tobler LH, Busch MF, McHutchison JG, Goldstein DB, Carrington M: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461(7262):789–801.
3. Tanaka Y, Nishida N, Sugiyama M, Kurokawa M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, To Y, Mita E, Tanaka E, Mochida M, Hirooka A, Hono Y, Itoh N, Uchiyama H, Toriike H, Muroyama S, Yoshida S, Hirose K, Nakagawa E, Kuroki T, Yoshida I, Kato K, Aoki T, Ito K, Nakanishi K, Shiba K, Moriyama S, Uchida T, Yokota Y, Uehara S, Kohyama T, Saito H, Aoki Y, Kodama S, Sato Y, Ito K, Murata K, Nomura H, Hige S, Adachi H, Hino K, Yatsuhashi H, Orto E, Kani S, Tanaka Y, Mizokami M: The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol 2011, 49(5):1853–60. DOI: 10.1128/JCM.02939-10.
4. Sugiyama M, Kimura T, Naoto S, Mukaide M, Shiinauchi T, Ueno M, Ito K, Murata K, Mizokami M: Development of specific and quantitative real-time detection PCR and immunoassays for α3-interferon. Hepatol Res 2012, 42(11):1089–99. doi:10.1111/j.1877-0589.2012.01302.x. Expub Jun 5 2012.
5. De Castellamau M, Aparicio E, Parera M, Franco S, Tural C, Cloet B, Martínez PM Deciphering the interleukin 28B variants that better predict response to pegylated interferon-alpha and ribavirin therapy in patients with chronic hepatitis C. Hepatology 2010, 52(6):1886–96. DOI: 10.1002/hep.23797.
6. Smith KR, Suppiah V, O’Connor K, Berg T, Weltman M, Abate ML, Sperlenghi L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afshari N: Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med 2011, 3(8):57.
7. Germer S, Holland MJ, Hijuchi R: High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. Genome Res 2000, 10(2):258–66.
8. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J: Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res 1982, 42(9):3585–63.
9. Drexler HG, Minowada J: History and classification of human leukemia-lymphoma cell lines. Leuk Lymphoma 1998, 31(4–5):305–16.
10. Schneider U, Schwenk HU, Bornkamm G: Characterization of EBV-genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 1977, 19(5):621–6.
11. Zhao LL, Hua X, He SF, Ren H, Qi Z: Interferon alpha regulates MAPK and STAT1 pathways in human hepatoma cells. Virology 2011, 411:1–7.
12. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M: Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007, 449(7164):919–22.
13. Shin EC, Seifert U, Kato T, Rice CM, Feinstone SM, Krolewski PM, Rehermann B: Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest 2005, 116(12):2906–14.
20. Zhang L, Alg N, Shao RX, Lin W, Fusco DN, Zhao H, Goto K, Peng LF, Chen WC, Chung RT. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 2011, 55(2):289–98.

21. Gondois-Rey F, Dental C, Hallon P, Baumert TF, Olive D, Hirsch I. Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS One 2009, 4(2):e4319.

22. Helbig KJ, Ruszkiewicz A, Semenic L, Harley HA, McColl SR, Beard MR. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology 2004, 39(5):1220–9.

23. Diegelmann J, Beigel F, Zitzmann K, Kaul A, Goke B, Auernhammer CJ, Bartenschlager R, Diepolder HM, Brand S. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS ONE 2010, 5(12):e15200.

24. Knapp S, Warshow U, Ho KM, Hegazy D, Little AM, Fowell A, Alexander G, Knapp et al. BMC Medical Genetics 2014, 15:104

25. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk S, Warshow U, Ho KM, Hegazy D, Little AM, Fowell A, Alexander G, Knapp et al. BMC Medical Genetics 2014, 15:104

26. Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP. Allelic variation in IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013, 45(2):164–71.

27. Lo HS, Wang Z, Hu Y, Yang HH, Gere S, Buetow KH, Lee MP. Allelic variation in gene expression is common in the human genome. Genome Res 2003, 13(8):672-682.

28. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergodt D, Porter-Gill P, Mumy A, Khoaar I, Chen S, Brand N, Tanway M, Liu L, Sleijfer S, Emmerich M, Bonkovsky H, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehmann B, Donnelly RP, O'Brien TR. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013, 45(2):164–71.

29. Biber S, Rotger T, Calandra T, Bochud M, Cerny A, Semmo N, Duong FH, Giebach T, Mallinverni R, Moradpour D, Negro F, Mullhaupt B, Bochud PY. Swiss Hepatitis C Cohort Study: IL28B expression depends on a novel TT/G polymorphism which improves HCV clearance prediction. J Exp Med 2013, 210(1):109–16.

30. McFarland AP, Homer SM, Jarret A, Jostlyn RC, Birdeveldt E, Shapiro BA, Delker DA, Hagedorn CH, Carrington M, Gale M Jr, Savan R. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014, 15(1):72–9. doi:10.1038/ni.2758. Epub 2013 Nov 17.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Cite this article as: Knapp et al. Detection of allelic specific differences in IFNL3 (IL28B) mRNA expression, BMC Medical Genetics 2014 15:104.